Arrowhead's first dual-target RNAi drug slashes both cholesterol and triglycerides in early trial
What's the data? On 15 September 2026, Arrowhead Pharmaceuticals reported interim results from its Phase 1/2a trial of ARO-DIMER-PA, the company's first "dual-functional" RNAi drug. RNAi (ribonucleic acid interference) medicines use small molecules that switch off specific genes; this one is designed to silence two genes with a single drug. In patients with mixed hyperlipidemia — dangerously high blood fats, combining high LDL ("bad") cholesterol and high triglycerides — a single dose cut levels of PCSK9, a liver protein that raises LDL cholesterol, by 72%, and APOC3, a protein that raises triglycerides, by 88% at peak effect. That translated into LDL cholesterol down 54%, triglycerides down 73%, non-HDL cholesterol down 61% and ApoB, a protein that tracks the artery-clogging particles in blood, down 50%.
Why it matters: Most medicines for heart-disease risk target either cholesterol or triglycerides; a single injection that switches off both pathways at once could help patients whose blood fats remain high on existing therapies. Single-dose testing is complete up to 400 mg with no drug-related serious side effects — the most common issues were injection-site reactions and headaches — and the study is continuing with repeat doses to establish safety and tolerability. The readout marks Arrowhead's push into cardiovascular disease alongside its plozasiran programme, and supports the start of broader testing of the dual-target approach.
Read more: Arrowhead Pharmaceuticals, 15 September 2026 · Yahoo Finance, 15 September 2026